The present study demonstrated that the administration of fermented Vigeo extract has a therapeutic effect on Dex-induced mouse skeletal muscle atrophy in vivo and that the efficacy of Vigeo might be regulated by inhibiting the proteolytic degradation system through AMPK/Sirt-1/PGC1α and Akt/mTOR signaling in C2C12 myoblast cells in vitro. This evidence concerns the gene AKT1 and muscle atrophy.